Milestone Scientific (MLSS) Q2 2025: International Revenue Jumps 48% as Leadership Targets Focused Medical Expansion
Milestone Scientific delivered a 25% revenue increase in Q2, fueled by surging international dental sales and initial traction in its medical segment. The company’s new leadership team is shifting strategy toward focused, data-driven adoption in select medical clinics, while maintaining disciplined cost control and direct-to-dental e-commerce. Execution in reimbursement, targeted hiring, and geographic precision are now central to the growth agenda, as management pivots from broad market pursuit to pragmatic, evidence-based scaling.
Summary
- International Dental Surge: Nearly half of revenue came from international markets, driven by new distributors and large orders.
- Focused Medical Push: Management is concentrating adoption efforts in a handful of clinics to build reimbursement proof points.
- Leadership Reset: New CEO and commercial team emphasize disciplined execution and targeted expansion over broad pursuit.
Performance Analysis
Milestone Scientific posted a 25% revenue increase in Q2, reaching $2.3 million, with international sales representing 48% of total revenue. This growth was largely attributed to the dental segment, where international sales more than doubled, reflecting a rebound in distributor engagement and the effect of larger, lumpy orders. The company’s direct-to-clinic e-commerce model, dental software-enabled platform for online sales to dental clinics and Dental Service Organizations (DSOs), continued to support margin expansion and customer retention, even as domestic sales remained flat.
Medical segment revenue remains nascent but improved modestly, supported by early Medicare Part B reimbursement wins for the CompuFlow epidural system. Gross profit expanded to $1.6 million, while operating losses narrowed to $1.5 million, reflecting tighter control of selling, general and administrative expenses. Inventory management and tariff mitigation strategies have insulated near-term cost structure, with sufficient inventory stockpiled to buffer against import volatility.
- International Revenue Mix Shift: International revenue accounted for 48% of the quarter, amplifying exposure to order timing and distributor engagement.
- Medical Revenue Still Small: Medical sales remain a minor contributor, but early reimbursement traction is a strategic milestone.
- Operating Losses Narrow: Loss from operations improved by nearly $300,000 year-over-year, as cost discipline offset higher SG&A.
Cash and working capital remain adequate for near-term needs, with no long-term debt and $1.3 million in cash. The company’s performance reflects both the opportunity and volatility inherent in its evolving business mix.
Executive Commentary
"We have a world-class products, an expanding base of loyal customers, and now a leadership team and expanded board with the experience and drive to unlock the next phase of growth... My focus now is disciplined execution, accelerating adoption, and ensuring that Milestone delivers innovation, growth, and long-term value for our shareholders."
Eric Hines, Chief Executive Officer
"The international growth was due to additional distributors, larger orders coming in, timing of when we're getting the orders out, and doing a better job of reaching some of our distributors that had fell off previously for different reasons, and just making a headway to get everything out timely."
Keisha Harkam, Vice President of Finance
Strategic Positioning
1. Precision in Medical Expansion
Leadership is abandoning the prior “boil the ocean” approach in favor of targeted, data-driven adoption within select pain management clinics in approved Medicare jurisdictions. The near-term strategy is to collect robust clinical and reimbursement data from a small set of clinics, ensuring proof of value and payment before broader rollout. This “lighthouse account” strategy is designed to build a replicable playbook for scaling, while mitigating resource dilution.
2. Reimbursement as Growth Catalyst
Securing Medicare Part B payment assignment under CPT code 077T for the CompuFlow epidural system is a foundational milestone, opening a reimbursement pathway for millions of procedures. Management is now investing in specialist hires and board expertise to accelerate claims processing, data collection, and payer engagement, recognizing that reimbursement clarity is the linchpin for medical adoption.
3. Dental Segment as Cash Engine
The company’s e-commerce dental business remains the primary revenue and margin driver, enabling direct relationships, higher repeat orders, and improved customer engagement. International expansion, while lumpy, has delivered outsized growth, and leadership is doubling down on targeted marketing and direct sales to capture further share in both existing and new markets.
4. Inventory and Tariff Management
Proactive inventory build-up and direct shipping from China to international partners have insulated the business from tariff risk, ensuring supply continuity and cost predictability. This forward-looking logistics strategy is key to supporting both domestic and international sales growth.
5. Leadership and Governance Overhaul
Recent appointments, including a new CEO, global head of sales, and board members with reimbursement and medical device expertise, signal a shift toward operational rigor and commercial scaling. The team’s background in healthcare distribution and reimbursement is expected to drive sharper execution and more disciplined capital allocation.
Key Considerations
This quarter marks a strategic inflection, as Milestone pivots from diffuse market pursuit to focused, data-backed scaling in its medical segment and disciplined expansion in dental.
Key Considerations:
- Medical Focus on Pain Management Clinics: Leadership is prioritizing pain management settings for CompuFlow, aiming to build a strong reimbursement case before expanding to new indications or geographies.
- International Order Volatility: Large, lumpy international dental orders can drive quarter-to-quarter swings, requiring careful forecasting and distributor management.
- Reimbursement Data as Adoption Lever: The business is investing in claims support and data collection to secure consistent payer coverage, a prerequisite for scaling medical device sales.
- Tariff and Inventory Buffer: Advanced planning and direct shipping have reduced near-term tariff exposure, but ongoing vigilance is needed as trade policy evolves.
- Leadership Depth and Accountability: New hires bring sales, distribution, and reimbursement expertise, but execution will be tested as the company shifts from vision to results.
Risks
Milestone’s medical growth remains highly dependent on successful reimbursement execution and data validation in a limited number of clinics. International sales are subject to order lumpiness and distributor reliability, while broader macroeconomic or regulatory shifts in tariffs and healthcare policy could introduce volatility. Execution risk is elevated as the new team transitions from strategy to operational delivery, and cash burn will require ongoing discipline absent a material ramp in medical adoption.
Forward Outlook
For Q3 2025, Milestone Scientific signaled:
- Continued focus on expanding medical reimbursement data in select clinics
- Ongoing international dental sales growth, with expected order lumpiness
For full-year 2025, management maintained a disciplined approach:
- Emphasis on cost control and cash preservation while investing in targeted medical and dental expansion
Management highlighted several factors that will drive progress:
- Hiring reimbursement specialists and leveraging board expertise to accelerate claims validation
- Maintaining direct-to-dental e-commerce and expanding distributor relationships internationally
Takeaways
Milestone’s Q2 results reflect a company at an operational turning point, with a reinforced leadership team and a more focused, data-driven approach to scaling its medical business.
- International Dental Strength: The dental segment’s international surge validates the direct sales and distributor model, but exposes the business to order timing swings.
- Medical Execution Remains the Critical Hurdle: Early reimbursement traction is promising, yet the pace and breadth of adoption will hinge on disciplined data collection and payer engagement in core clinics.
- Investor Focus for Coming Quarters: Watch for evidence of sustained medical adoption, margin preservation in the face of international volatility, and further progress in reimbursement wins and claims processing.
Conclusion
Milestone Scientific is entering a new phase defined by targeted execution, operational discipline, and leadership accountability. The company’s ability to translate focused medical adoption and international dental momentum into sustainable, profitable growth will be the key investor watchpoint for the remainder of 2025.
Industry Read-Through
Milestone’s experience underscores the growing importance of reimbursement clarity and clinical data in scaling novel medical devices, especially for smaller companies seeking to penetrate regulated healthcare markets. The volatility in international dental orders highlights the necessity for robust distributor relationships and inventory strategies in global medtech. Other device makers should note the value of disciplined, lighthouse-focused adoption and the risks of diffuse, unfocused expansion, as well as the ongoing need to buffer against trade policy shocks and macroeconomic headwinds.